Andere Kunden interessierten sich auch für
![Drug tests in India]( "Drug tests in India")
Drug tests in India18,95 €![Ethical and Responsibility Challenges and Opportunities arising from the COVID-19 Crisis. Focusing on the Pharmaceutical Sector the Example of the Bayer AG]( "Ethical and Responsibility Challenges and Opportunities arising from the COVID-19 Crisis. Focusing on the Pharmaceutical Sector the Example of the Bayer AG")
Ethical and Responsibility Challenges and Opportunities arising from the COVID-19 Crisis. Focusing on the Pharmaceutical Sector the Example of the Bayer AG17,95 €![The Future of Work in Pharmaceutical Production]( "The Future of Work in Pharmaceutical Production")
The Future of Work in Pharmaceutical Production18,95 €![Drug and alcohol testing of employees and privacy rights]( "Drug and alcohol testing of employees and privacy rights")
Drug and alcohol testing of employees and privacy rights17,95 €![DISASTERS' IMPACT ON DRUG SUPPLY]( "DISASTERS' IMPACT ON DRUG SUPPLY")
DISASTERS' IMPACT ON DRUG SUPPLY25,99 €![Mergers & Acquisitions and Stock Returns in the US Technology, Media & Telecommunications Sector. How the Impact Has Changed Over Time]( "Mergers & Acquisitions and Stock Returns in the US Technology, Media & Telecommunications Sector. How the Impact Has Changed Over Time")
Mergers & Acquisitions and Stock Returns in the US Technology, Media & Telecommunications Sector. How the Impact Has Changed Over Time42,95 €![Emerging trends and developments of country-specific defense strategies against hostile takeovers]( "Emerging trends and developments of country-specific defense strategies against hostile takeovers")
Emerging trends and developments of country-specific defense strategies against hostile takeovers44,99 €
Master's Thesis from the year 2013 in the subject Business economics - Miscellaneous, grade: 8,5 (NL, äquivalent zu 1,2), Utrecht University (Law, Economics and Governance), course: Mergers & Akquisitions, language: English, abstract: The number and volume of pharmaceutical companies' mergers and acquisitions have reached exorbitant magnitudes in the last decade, with estimations of over 1,300 deals worth US$ 690 billion between 2000 and 2009.1 The biggest transaction, valued at US$ 66.7 billion2, occurred in 2009 when Pfizer bought Wyeth. The sheer dimension of transactions in this sector, being subject to significant public interest, poses questions about the motivations behind these deals, which are mostly believed to be countermeasures for patent expirations, as well as the impact on drug innovation.Even though, the regular object of interest regarding mergers is the shareholder value, in this specific case drug innovation is of particular interest as it does not only influence the future prospects of the pharmaceutical companies but also long term public health. Hence, the objective of this thesis is to discover what the impact of pharmaceutical mergers on R&D intensity and efficiency of the acquiring organization and on the pharmaceutical industry as a whole is.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.